Category Archives: Immunology

Immunology

Assistant/Associate Professor in Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 239789 – Times Higher Education (THE)

Job Description

The Department of Medical Microbiology & Immunology, College of Medicine and Health Sciences (CMHS), UAE University, seeks candidates for a faculty position at the rank of Assistant/Associate Professor in Immunology. Outstanding candidates working in all areas of immunology are invited to apply. We are particularly looking for an innovative investigator with a strong research productivity who has an established, or a clear potential to establish, an independent research program.

Candidates with experience in translational immunology research and with a strong background in computational and systems biology, genomics or bioinformatics will be preferred. Screening of applications will continue until the position is filled. The College of Medicine operates an internationally recognized, integrated, problem/team-based learning curriculum and provides excellent research facilities. English is the language of instruction. Areas of research within the Department include integrative immunology approaches to study cancer immunity and immunotherapy, mechanisms of autoimmune disorders, molecular epidemiology of human bacterial pathogens and antibiotic resistance, development of retroviral vectors for gene therapy, EBV and its role in the pathogenesis of human diseases and public health, neuroimmune regulatory pathways, and host-pathogen interactions.

Minimum Qualification

The successful candidate must have a PhD or MD/PhD from an accredited institution. The candidate should have a strong track record of research in immunology. It is expected that the appointee will also have experience in teaching medical and postgraduate students. Importantly, candidates must demonstrate the potential to establish an independent and sustained research program in their area of expertise and be able to obtain peer-reviewed internal and external funding.

Preferred Qualification

As above.

Division College of Medicine&Health Sciences

Department Microbiology - (CMHS)

Job Close Date open until filled

Job Category Academic - Faculty

Salary 30000-40000 UAE Dirhams per month, based on experience

Read more:
Assistant/Associate Professor in Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 239789 - Times Higher Education (THE)

Immunology

Lasting immunity against Covid-19 found after mild or asymptomatic infection: Study – Hindustan Times

Scientists have found evidence of protective immunity against Covid-19 in people up to four months after mild or asymptomatic coronavirus infection, providing hope for the long-lasting efficacy of vaccines.

The researcher, including those from Queen Mary University of London analysed antibody and T cell responses in 136 healthcare workers in the UK, who had mild or asymptomatic Covid-19 infection dating back to March.

The study, published in the journal Science Immunology, found that 89 per cent of healthcare workers analysed carried neutralising antibodies 16-18 weeks after infection.

The team, also involving researchers Imperial College London and University College London, UK, found most workers also had T cells capable of recognising multiple different parts of the virus.

However, they noted that the two responses did not always persist in harmony, with some individuals showing T cell immunity but no evidence of antibodies, and vice versa.

Our study of SARS-CoV-2 infection in healthcare workers from London hospitals reveals that four months after infection, around 90 per cent of individuals have antibodies that block the virus, Joseph Gibbons, a Postdoctoral Research Assistant at Queen Mary, said.

Even more encouragingly, in 66 per cent of healthcare workers we see levels of these protective antibodies are high and that this robust antibody response is complemented by T cells which we see reacting to various parts of the virus, Gibbons said.

Describing the finding as good news, he explained that if someone has been infected with the coronavirus, there is a good chance that they will have developed antibodies and T cells that may provide some protection in case they encounter the virus again.

Much of the debate on protective immunity has focussed on the different roles of B cells, which make antibodies, and T cells, white blood cells which help protect from viruses, including direct killing.

The latest study found that while protective antibody responses were usually complemented by a T cell response, over half of the healthcare workers had different antibody and T cell responses.

The workers did not produce a T cell response specific to proteins found on the outer layer of the SARS-CoV-2 virus.

The research also found that T cell responses tended to be higher in those with the classic, defining symptoms of Covid-19, while asymptomatic infection resulted in a weaker T cell immunity than symptomatic infection, but equivalent neutralising antibody responses.

The new study also provides reassurance for vaccination efforts, suggesting that even following mild infection, individuals carry antibody and T cell immunity to many parts of the virus, known as epitopes.

The researchers noted that while new variants are appearing, the changes to the virus dont necessarily occur within these epitopes so it is hoped the vast majority of immune recognition can likely continue unperturbed.

Our study in asymptomatic and mild cases gives a positive insight into the durability of immunity to SARS-CoV-2 after four months of infection, Corinna Pade, a Postdoctoral Research Scientist at Queen Mary, said.

The researchers noted that it is an important finding as mild or even no symptoms of Covid-19 are very common and representative of most infections in the community.

Such abundant immune responses also give hope for the long-lasting efficacy of vaccines, Pade added.

(This story has been published from a wire agency feed without modifications to the text.)

Follow more stories on Facebook and Twitter

Read the original post:
Lasting immunity against Covid-19 found after mild or asymptomatic infection: Study - Hindustan Times

Immunology

Covid jab supply will be biggest cause of delay in Irish rollout as Pfizer dont have enough to go around, e – The Irish Sun

THE supply and availability of the Covid-19 vaccine will be the biggest cause of delays in Ireland's rollout, an immunologyexpert said.

Professor of Experimental Immunology at Trinity College Dublin, Kingston Mills, said Pfizer do not have enough of the jab to go around, and are cranking up manufacturing to meets countries' needs.

3

3

3

Ireland's first doses of the jab will be administered this week at four hospitals, with a roll-out beginning nursing homes after.

Health Minister Stephen Donnelly has predicted that Ireland will see up to 20,000 people vaccinated a week from early January on.

Professor Mills said supply and availability of doses will be the largest challenge in Ireland's roll-out.

Speaking on Newstalk's Late Breakfastwith Mark Cagney, Prof Mills said: "I think what's going to delay the rollout is the supply and availability of vaccine.

We have currently got quite a small number of doses, only 10,000, so we are going to get through that quite quickly.

"So the delay in getting into health care workers and nursing homes is supply.

Pfizer just dont have enough of this vaccine to go around for all the countries that want it yet.

"They are going to be cranking up the manufacturing now and hopefully that will be solved in the weeks and months ahead.

According to Prof Mills, transparency is key in the vaccine roll-our in order to ensure successful uptake.

He said: There are huge benefits that is the thing that has to be said with these vaccines.

90 per cent of people 95 per cent in the cases of Pfizer will not get Covid if they are vaccinated. That is what the clinical trials show so that is a huge, huge benefit.

There were some side-effects. People got some injection site reactions; some people got a slight fever. These are all transient events that are often association with vaccination.

They need to be spelled out to the public and transparency is key to all of this.

"Making sure that everyone knows about any potential issues and then if people get a slight reaction, they will know that was common enough based on the clinical trial and it shouldnt be a problem.

Meanwhile, Tanaiste Leo Varadkar has said Covid-19 restrictions over the coming weeks must be "sustainable" and may be in place for a "long period".

TheFine Gaelleader explained that the availability of the vaccine has "changed things" in regards to reopening the country.

And he said restrictions should be in place until the vulnerable are vaccinated.

Varadkar told RTE Radio One's Morning Ireland: "The availability of the vaccine does change things now.

"We can actually now foresee the point in which well have vaccinated those most at risk, the very elderly, people in residential care and healthcare workers.

"I think there is a case for saying that restrictions that are in place should stay in place until thats done.

plane wrongDrunk Brit who forced Jet2 flight diversion to Cork Airport fined 1.5k

sharp increase765 new cases as CMO says 3rd wave of Covid hospitalisations higher than 2nd

urgent recallGinger powder recalled over chemical contaminants known to cause cancer

nothing to cie hereAims to stop publishing of report into Mayo train crash that injured 86

silver liningDuty free shopping for passengers travelling between Ireland & UK to return

power outFresh Irish wind alert for 110kph gusts as 1k without power in Bella aftermath

"But that also, needs to then be reflected in the kind of restrictions we put in place because they need to be sustainable for a long period.

"Theyre not just for three or four weeks."

Varadkar said that the Cabinet plan to review the restrictions on January 12 and that has not changed.

Read the original post:
Covid jab supply will be biggest cause of delay in Irish rollout as Pfizer dont have enough to go around, e - The Irish Sun

Immunology

Secondary Bloodstream Infections Associated With Severe COVID-19 and Worse Health Outcomes – SciTechDaily

People with severe COVID-19 who had secondary bloodstream infections were sicker, had longer hospital stays and worse health outcomes, Rutgers study finds.

People with severe COVID-19 and a secondary blood infection were significantly sicker upon hospital admission, had longer hospital stays, and poorer outcomes, according to a Rutgers study.

The study, published in the journal Clinical Infectious Diseases, is the first to assess the microbiology, risk factors, and outcomes in hospitalized patients with severe COVID-19 and secondary bloodstream infections.

The researchers looked at 375 patients diagnosed with severe COVID-19 from March to May 2020. Of that group, they sampled 128 cases that had secondary bloodstream infections, 92 percent of which were bacterial infections.

These patients were more likely to have altered mental status, lower percent oxygen saturation, septic shock and to be admitted to the intensive care unit compared to those without bloodstream infections, said co-lead author Pinki Bhatt, an assistant professor at Rutgers Robert Wood Johnson Medical Schools Division of Allergy, Immunology and Infectious Disease.

The researchers also found that patients who needed more advanced types of supplemental oxygen upon hospital admission had higher odds of secondary bloodstream infections.

The in-hospital mortality rate for these patients was more than 50 percent, but the study reported these deaths were associated with, not caused by, the condition.

According to the study, infections in COVID-19 patients may have contributed to the severity of illness or it may reflect other underlying physiological and immunological complications of COVID-19.

The study showed that the most common cause of secondary blood stream infections was unknown or not determined followed by central-line associated bloodstream infection as the most common presumed source.

The study found that 80 percent of all the patients in the study received antimicrobials at some point during hospitalization, including those who did not have bloodstream infections. This likely reflects clinicians inclination to administer antimicrobials given the limited information on the natural course of this novel disease, Bhatt said. She noted that further studies are needed to better understand when to suspect and treat empirically for secondary bloodstream infections in severe COVID-19.

Reference: Risk Factors and Outcomes of Hospitalized Patients With Severe Coronavirus Disease 2019 (COVID-19) and Secondary Bloodstream Infections: A Multicenter Case-Control Study by Pinki J Bhatt, Stephanie Shiau, Luigi Brunetti, Yingda Xie, Kinjal Solanki, Shaza Khalid, Sana Mohayya, Pak Ho Au, Christopher Pham, Priyanka Uprety, Ronald Nahass, Navaneeth Narayanan, 20 November 2020, Clinical Infectious Diseases.DOI: 10.1093/cid/ciaa1748

Other Rutgers authors include Stephanie Shiau, Luigi Brunetti, Yingda Xie, Kinjal Solanki, Shaza Khalid, Sana Mohayya, Pak Ho Au, Christopher Pham, Priyanka Uprety and Ronald Nahass.

Read more:
Secondary Bloodstream Infections Associated With Severe COVID-19 and Worse Health Outcomes - SciTechDaily

Immunology

Medical Musings: Scientist ushered in science of immunology, ability to produce vaccines with landmark 1885 treatment – Daily Press

Louis Pasteurs method for zapping the germs from fresh milk changed the way people bought and consumed dairy, and today many more food products are pasteurized for safety. Pasteurs work was one of the most immediate consequences of germ theory, where he worked to kill something invisible to the naked eye that nonetheless could cause grave illness.

See original here:
Medical Musings: Scientist ushered in science of immunology, ability to produce vaccines with landmark 1885 treatment - Daily Press

Immunology

For immunologists, 2020 has been a terrifying, incredible year – The Guardian

You may think of immunologists as biologists, but we are also in the defence business. This aspect of our role really comes into its own when a new, devastating disease rears its head. We estimate that the new coronavirus Sars-CoV-2 first made the leap to humans last December. Over one and a half million lives have been lost in the past year as a result. Dealing with Covid has undoubtedly left its mark on the field my field and it seems like a good time to take stock.

Right now I am sitting opposite my Christmas tree, the cat beside me, and I cant help thinking that swooning over That Plot from the Pfizer-BioNTech Covid-19 vaccine briefing (page 58 if you are interested) is probably a phenomenon restricted to viral immunologists. But if this year has taught us anything, its not to make assumptions. And sure enough, Ive seen it shared on social media by non-scientists as a symbol of hope.

Its been quite the journey to get to that graph. In March we were asked to go home, shut down our labs and think of things for our students and staff to do. It was unclear whether many of them would be eligible for furlough. Research students had to teach themselves new skills, trying their hand at programming languages and science writing. Masters students switched to dry projects, forgoing the coveted lab experience that is often the main point of an expensive MRes degree.

Postdocs, who are on contracts, entered a new era of uncertainty. Universities were forced to implement hiring freezes and funding bodies deferred or cancelled grant schemes. Academics with clinical backgrounds went back to frontline duties, their research stagnating but, thankfully, their salaries secure. Nevertheless, their risk of catching a new dangerous disease increased, and PPE was in short supply. Non-clinicians were seriously worried about how student recruitment would affect universities income and their job security by association. It was clear that there would be tough times ahead.

At the same time as all this insecurity, there was a buzz of intellectual excitement in viral immunology: a new virus, an unknown entity. We had so many questions! We consumed preprints a version of a scientific paper that precedes peer review with a desperate thirst. It takes months to put a scientific paper through peer review, but preprints share the data immediately for all to see and can help shape the next steps in disease prevention and treatment. Immunologists worked with journalists to evaluate and interpret new findings on a daily basis, and this has increased the publics trust in science.

I fangirled over my viral immunology heroes as they appeared on broadcast media and in the popular press, dispelling misinformation and flying the flag for evidence-based medicine. In 1663, the Royal Society of London for Improving Natural Knowledge was formed under the motto Nullius in verba, which can be glossed as take nobodys word for it.

Back then, fellows met at the societys premises to promote and defend their research under the harsh questioning of their peers. In 2020, however, we had lockdowns.

One of the best parts of my job is travelling to meet with scientists, learning about their discoveries and forging relationships that lead us down new and fruitful paths. Scientists know no borders, and being stuck at home during the pandemic has hindered the emergence of new collaborations.

On the other hand, we took to meeting remotely like ducks to water; immunologists are now equipped to attend a seminar presented by a colleague from the other side of the planet, while feeding their children lunch and moving the laundry to the dryer. Caring responsibilities while working from home have given rise to hilarious memes, but have also caused a huge amount of stress, and it is estimated that women have and will be disproportionately affected. The resulting decrease in productivity is likely to impact womens career progression in the years following the pandemic, and scientists and funders are looking for solutions.

The economic after-effects of the pandemic will hold back research in some areas of immunology for years to come, because so much discovery science relies on funding from charities that are currently in dire straits. On the other hand, governments have diverted resources to coronavirus projects to cope with the new healthcare challenges. Academics have collaborated with industry to speed up vaccine development and drug discovery, and expensive clinical trials have experienced no trouble getting support. As a result, the first Covid-19 vaccine was rolled out less than a year from the discovery of the virus, and there are plenty more to come.

The pandemic has acted as a proof-of-concept test for the idea that investing in scientific discovery is crucial for humanitys health and economic prosperity. If we put money into science and work together, we can take on global challenges with resounding success. For example, we are now laying the foundations of the infrastructure needed to deploy vaccines globally, and we will be able to use this to target diseases other than coronavirus with prophylactic and therapeutic vaccination. This will include autoimmune diseases and cancer as well.

I dont need to tell you that its been a terrible year in terms of human suffering. But I take comfort from the fact that its also been a year that proved how powerful not just immunology, but science as a whole, can be.

Zania Stamataki is a senior lecturer in viral immunology at the Institute for Immunology and Immunotherapy, University of Birmingham

See more here:
For immunologists, 2020 has been a terrifying, incredible year - The Guardian

Immunology

American College of Allergy, Asthma, and Immunology Updates Guidance on Risk of Allergic Reactions to mRNA COVID-19 Vaccines – Newswise

ARLINGTON HEIGHTS (Dec. 22, 2020) Following reports of some patients experiencing anaphylaxis after getting a COVID-19 vaccine, theCDC has issued guidance related to COVID-19 vaccines and severe allergic reactions. Specifically, the CDC recommends patients experiencing a severe allergic reaction after getting the first shot should not get the second shot. The CDC also says that doctors may refer these patients to a specialist in allergies and immunology to provide more care or advice.

Reactions to vaccines, in general, are rare, with the incidence of anaphylaxis estimated at 1.31 in 1 million doses given. With the FDA emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine on December 11, 2020 and the Moderna vaccine on December 18, 2020, the ACAAI COVID-19 Vaccine Task Force recommends the following guidance for physicians and other providers related to risk of an allergic reaction on vaccination.

These recommendations are based on best knowledge to date but could change at any time, pending new information and further guidance from the FDA or CDC.

Editors note: Please contact Hollis Heavenrich-Jones hollisheavenrich-jones@acaai.org 847-725-2277 if you would like to interview a member of the ACAAI Covid Task Force on the topic of allergic reactions to the vaccines.

About ACAAI The ACAAI is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administer immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visit AllergyandAsthmaRelief.org. Join us on Facebook, Pinterest and Twitter.

References

McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults.J Allergy Clin Immunol. 2016; 137(3):868-878.

Dreskin et al. International Consensus (ICON): allergic reactions to vaccines.World Allergy Organization Journal2016; 9:32.

Wylon, K., Dlle, S. & Worm, M. Polyethylene glycol as a cause of anaphylaxis.J Allergy Asthma Clin Immunol.12,67 (2016).

Stone CA, Liu Y, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized.J Allergy Clin Immunol Pract.2019; 7(5): 15331540.

Sellaturay P, et al. Polyethylene GlycolInduced Systemic Allergic Reactions (Anaphylaxis),J Allergy Clin Immunol Pract.2020.

See the article here:
American College of Allergy, Asthma, and Immunology Updates Guidance on Risk of Allergic Reactions to mRNA COVID-19 Vaccines - Newswise

Immunology

Dangerous Side Effects of Your Christmas Tree, According to Science | Eat This Not That – Eat This, Not That

If you find yourself sneezing or wheezing this holiday season, it may not only be because you're overly emotional about that new robe your kids got you. It may be because of "Christmas tree syndrome." Approximately 5 percent of Americans are allergic to mold, and your treelive or artificialmay be spreading it in your house. "Mold can cause many health effects," says the CDC. Read on to see how this might affect youand speaking of illnesses, to ensure your health and the health of others, don't miss these Sure Signs You've Already Had Coronavirus.

Mold and pollen are common irritants. "Live pine trees can cause problems for those with asthma," reports the American Academy of Allergy Asthma & Immunology. "They can bring mold and pollen into your home." "For some people, mold can cause a stuffy nose, sore throat, coughing or wheezing, burning eyes, or skin rash," says the CDC. "People with asthma or who are allergic to mold may have severe reactions. Immune-compromised people and people with chronic lung disease may get infections in their lungs from mold."

"The trees themselves most likely have mold spores and pollen on them that are brought into the home," Melanie Carver, vice president of community health and marketing for the Asthma and Allergy Foundation of America, told the Detroit News. "Mold grows in warm, humid environments, and sometimes the inside of your home provides the perfect conditions to encourage mold growth."

"Artificial trees and decorations stored in a garage or basement can have mold and dust on them. Be sure to wipe down the decorations and wash the tree stand," advises the American Academy of Allergy Asthma & Immunology. "Cardboard boxes and open bags allow dust to accumulate. Switch to storage containers that keep out dust mites. If you have room, store your decorations and artificial tree in a temperature-controlled part of your home to cut down on moisture."

"Christmas trees are a possible source of mold exposure during the holiday season," says Philip Hemmers, an allergist and immunologist with St. Vincent's Medical Center in Bridgeport, Conn, who co-authored a study about Christmas trees and allergies. "Mold allergies peak in the fall, and we see a second peak with a lot of our mold-sensitive patients during the holiday season. Our finding correlates with this second peak of mold sensitivity."

RELATED: Simple Ways to Never Age, According to Experts

"Hose down your live tree to knock off mold, pollen and dirt," recommends the American Academy of Allergy Asthma & Immunology. "Let it dry for a few days in a garage, or outside if it's warm enough, before you bring it inside." "Around five to seven days would probably be a good amount of time to have a live Christmas tree up, since after seven days the mold count starts to increase exponentially," Dr. Sharmilee Nyenhuis, an allergist at the University of Illinois at Chicago, told the Detroit News. As for yourself, to have the happiest of holiday seasons, and to protect your life and the lives of others, don't miss these 35 Places You're Most Likely to Catch COVID.

Visit link:
Dangerous Side Effects of Your Christmas Tree, According to Science | Eat This Not That - Eat This, Not That

Immunology

New research highlights the importance of the thymus in successful pregnancies – University of Birmingham

Researchers found that during pregnancy, the female sex hormones instruct the thymus to produce Tregs specialised in dealing with physiological changes during pregnancy.

How the immune system adapts to pregnancies has puzzled scientists for decades. Now, findings from an international group of researchers, led by experts at Karolinska Institutet in Sweden, reveal important changes that occur in the thymus to prevent miscarriages and gestational diabetes. The study was published today (23 December 2020) in Nature.

The thymus is a central organ of the immune system where specialised immune cells called T lymphocytes mature. These cells, commonly referred to as T cells, then migrate into the blood stream and tissues to help combat pathogens and cancer. An important T cell subset, known as a regulatory T cell or Treg, is also produced in the thymus. The main function of a Treg is to help regulate other immune cells.

Researchers found that during pregnancy, the female sex hormones instruct the thymus to produce Tregs specialised in dealing with physiological changes during pregnancy. The studywhich involved researchers at Karolinska Institutet, the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, University of British Columbia in Vancouver, further reveals that RANK, a receptor expressed in the thymus epithelia, is the key molecule behind this mechanism.

The study builds on work by a team at the University of Birmingham as researcher and collaboratorProfessor Graham Andersonfrom the Institute of Immunology and Immunotherapy explains: In 2007, our lab provided the first evidence that RANK plays a critical role in controlling thymus function in the steady state immune system. Now, this new research shows how RANK in the thymus regulates the immune system in pregnancy, which is an exciting new direction.

We knew RANK was expressed in the thymus, but its role in pregnancy was unknown, says first and co-corresponding author Dr. Magdalena Paolino, assistant professor at the Department of Medicine, Solna, Karolinska Institutet.

To get a better understanding, the authors studied mice where RANK had been deleted from the thymus.

The absence of RANK prevented the production of Tregs in the thymus during pregnancy. This resulted in less Tregs in the placentas, leading to miscarriages, continues Magdalena Paolino.

This latest study further shows that in normal pregnancies, the produced Tregs also migrate to the mothers fat tissue to prevent inflammation and help control glucose levels in the body. Pregnant mice lacking RANK had high levels of glucose and insulin in their blood and many other indicators of gestational diabetes, including fetal macrosomia.

Similar to babies of women with gestational diabetes, the newborn pups were much heavier than average, explains Magdalena Paolino.

In addition, the deficiency of Tregs during pregnancy was proven to result in long-lasting transgenerational effects on the offspring, which remained prone to diabetes and overweight throughout their life spans. Giving the RANK deficient mice thymus-derived Tregs that had been isolated from normal pregnancies, reversed all issues including fetal loss and maternal glucose levels and the body weights of the pups.

The researchers also analysed women with gestational diabetes, revealing a reduced number of Tregs in their placentas, much similar to the study on mice.

This research changes our view of the thymus, as an active and dynamic organ required to safeguard pregnancies, Magdalena Paolino says. It also provides new molecular insight for gestational diabetes, a disease that affects many women and which we still know little about. It emphasises the importance of clinics detecting and managing glucose metabolism in pregnant women to avert its long-term effects.

Co-corresponding author Dr. Josef Penninger notes that how rewiring of the thymus contributes to a healthy pregnancy was one of the remaining mysteries of immunology until now.

Our work over many years has now not only solved this puzzle pregnancy hormones rewire the thymus via RANK but uncovered a new paradigmatic function: the thymus not only changes the immune system of the mother to allow the fetus, but it also controls metabolic health of the mother, Josef Penninger says.

The study was possible thanks to a close collaboration between the laboratory of Magdalena Paolino at Karolinska Institutet and the laboratories of Josef Penninger at IMBA and UBC. Researchers from the CeMM Institute and the Medical University of Vienna, as well as from the Universities of Birmingham and Oxford also participated.

For more information please contactMagdalena Paolino, Assistant Professor,Department of Medicine Solna, Karolinska Institutet.

Full paper:RANK links thymic Tregs to fetal loss and gestational diabetes in pregnancy, Magdalena Paolino*, Rubina Koglgruber, Shane J. F. Cronin, Iris Uribesalgo, Esther Rauscher, Juergen Harreiter, Michael Schuster, Dagmar Bancher-Todesca, Blanka Pranjic, Maria Novatchkova, Andrea White, Verena Sigl, Sabine Dekan, Juan P. Fededa, Thomas Penz, Christoph Bock, Lukas Kenner, Georg A. Hollnder, Graham Anderson, Alexandra Kautzky-Willer, and Josef M. Penninger*, Nature, in press 23/12/2020

DOI:10.1038/s41586-020-03071-0.

Grant information:

The researchers were supported by grants from Karolinska Institutet, the Ragnar Soderberg Foundation, the Swedish Research Council, the Swiss National Foundation, The Wellcome Trust, MRC, CRUK, Austrian Science Fund, European Training Network, IMBA, a Canada150 Chair, the T. von Zastrow foundation and the European Research Council.

View original post here:
New research highlights the importance of the thymus in successful pregnancies - University of Birmingham

Immunology

ACAAI COVID-19 Task Force Members available to discuss allergic reactions to mRNA vaccines – Newswise

Niraj Patel, MD, MS, is Chief of the Division of Pediatric Infectious Disease and Immunology at Levine Childrens Hospital, in Charlotte, North Carolina. He is an Adjunct Associate Professor at the University of North Carolina Chapel Hill. Dr. Patel established the Charlotte Immunodeficiency Center of Excellence in 2009. He is board certified in pediatrics, pediatric infectious diseases, and allergy and immunology.

Dr. Patel chairs the American College of Allergy, Asthma and Immunology COVID-19 Task Force and is available to answer questions about allergic reactions to the mRNA COVID-19 vaccines.

Link:
ACAAI COVID-19 Task Force Members available to discuss allergic reactions to mRNA vaccines - Newswise